Premium
Antagonists of B 2 bradykinin receptors
Author(s) -
Steranka Larry R.,
Farmer Stephen G.,
Burch Ronald M.
Publication year - 1989
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.3.9.2545496
Subject(s) - bradykinin , b2 receptor , receptor , pharmacology , chemistry , medicine
Bradykinin and its active metabolites, produced by kallikreins at their sites of action, potently elicit a variety of biological effects: hypotension, bronchoconstriction, gut and uterine contraction, epithelial secretion in airway, gut, and exocrine glands, vascular permeability, pain, connective tissue proliferation, cytokine release, and eicosanoid formation. These effects are mediated by at least two broad classes of receptors. The most common is the B 2 subtype. The availability of competitive antagonists of B 2 receptors has provided powerful tools for the study of bradykinin's actions. The significance of kinins in certain human diseases is being explored by using these agents as potential therapeutic agents. Human clinical trials are under way to test the usefulness of bradykinin receptor antagonists to treat symptoms of the common cold and the pain associated with severe burns. Trials are also being comtemplated for use in treatment of asthma.—S teranka , L. R.; F armer , S. G.; B urch , R. M. Antagonists of B 2 bradykinin receptors. FASEB J. 3: 2019‐2025; 1989.